Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

HER2 mutation status in Japanese HER2-negative breast cancer patients.

Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, Sato S, Takahashi S, Fujii Y, Toyama T.

Jpn J Clin Oncol. 2014 Jul;44(7):619-23. doi: 10.1093/jjco/hyu053. Epub 2014 May 5.

PMID:
24803549
2.

HER2 mutation status in Japanese HER2-positive breast cancer patients.

Endo Y, Dong Y, Kondo N, Yoshimoto N, Asano T, Hato Y, Nishimoto M, Kato H, Takahashi S, Nakanishi R, Toyama T.

Breast Cancer. 2016 Nov;23(6):902-907. Epub 2015 Dec 7.

PMID:
26642960
3.

Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.

Cuadros M, Cano C, López FJ, López-Castro R, Concha A.

Pathobiology. 2013;80(1):32-40. doi: 10.1159/000339431. Epub 2012 Jul 24.

4.

Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.

Shah SS, Ketterling RP, Goetz MP, Ingle JN, Reynolds CA, Perez EA, Chen B.

Hum Pathol. 2010 Jan;41(1):103-6. doi: 10.1016/j.humpath.2009.07.001. Epub 2009 Sep 16.

PMID:
19762065
5.

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.

J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26.

PMID:
21947821
6.

A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.

Aoyama K, Kamio T, Nishikawa T, Kameoka S.

Jpn J Clin Oncol. 2010 Jul;40(7):613-9. doi: 10.1093/jjco/hyq019. Epub 2010 Mar 4.

PMID:
20202990
9.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

10.

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.

Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.

Cancer. 2016 Sep 1;122(17):2654-62. doi: 10.1002/cncr.30102. Epub 2016 Jun 10.

11.

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.

Bartlett JM, Munro A, Cameron DA, Thomas J, Prescott R, Twelves CJ.

J Clin Oncol. 2008 Nov 1;26(31):5027-35. doi: 10.1200/JCO.2007.14.6597. Epub 2008 Sep 2.

PMID:
18768436
13.

HER2 in breast cancer: a review and update.

Krishnamurti U, Silverman JF.

Adv Anat Pathol. 2014 Mar;21(2):100-7. doi: 10.1097/PAP.0000000000000015. Review.

PMID:
24508693
14.

The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.

Choi Y, Kim EJ, Seol H, Lee HE, Jang MJ, Kim SM, Kim JH, Kim SW, Choe G, Park SY.

Hum Pathol. 2012 Jan;43(1):48-55. doi: 10.1016/j.humpath.2010.08.026. Epub 2011 Jul 5.

PMID:
21733550
15.

Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.

Sasaki T, Fuse N, Kuwata T, Nomura S, Kaneko K, Doi T, Yoshino T, Asano H, Ochiai A, Komatsu Y, Sakamoto N, Ohtsu A.

Jpn J Clin Oncol. 2015 Jan;45(1):43-8. doi: 10.1093/jjco/hyu174. Epub 2014 Nov 6.

PMID:
25378649
16.
17.

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.

Teng YH, Tan WJ, Thike AA, Cheok PY, Tse GM, Wong NS, Yip GW, Bay BH, Tan PH.

Breast Cancer Res. 2011 Apr 1;13(2):R35. doi: 10.1186/bcr2857.

18.

Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.

Arihiro K, Oda M, Ogawa K, Tominaga K, Kaneko Y, Shimizu T, Matsumoto S, Oda M, Kurita Y, Taira Y.

Jpn J Clin Oncol. 2013 Jan;43(1):55-62. doi: 10.1093/jjco/hys187. Epub 2012 Dec 7.

PMID:
23225912
19.

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.

Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC.

Breast Cancer Res. 2005;7(6):R1028-35. Epub 2005 Oct 25.

20.

Supplemental Content

Support Center